Engineering organs

Anthony Atala

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Applications of regenerative medicine technology may offer novel therapies for patients with injuries, end-stage organ failure, or other clinical problems. Currently, patients suffering from diseased and injured organs can be treated with transplanted organs. However, there is a severe shortage of donor organs that is worsening yearly as the population ages and new cases of organ failure increase. Scientists in the field of regenerative medicine and tissue engineering are now applying the principles of cell transplantation, material science, and bioengineering to construct biological substitutes that will restore and maintain normal function in diseased and injured tissues. The stem cell field is also advancing rapidly, opening new avenues for this type of therapy. For example, therapeutic cloning and cellular reprogramming may one day provide a potentially limitless source of cells for tissue engineering applications. Although stem cells are still in the research phase, some therapies arising from tissue engineering endeavors have already entered the clinical setting successfully, indicating the promise regenerative medicine holds for the future.

Original languageEnglish
Pages (from-to)575-592
Number of pages18
JournalCurrent Opinion in Biotechnology
Volume20
Issue number5
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Tissue engineering
Regenerative Medicine
Tissue Engineering
Stem cells
Stem Cells
Cloning
Materials science
Cell Engineering
Bioengineering
Cell Transplantation
Therapeutics
Tissue
Organism Cloning
Tissue Donors
Technology
Wounds and Injuries
Research
Population

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Engineering organs. / Atala, Anthony.

In: Current Opinion in Biotechnology, Vol. 20, No. 5, 01.10.2009, p. 575-592.

Research output: Contribution to journalArticle

Atala, Anthony. / Engineering organs. In: Current Opinion in Biotechnology. 2009 ; Vol. 20, No. 5. pp. 575-592.
@article{ae42245167244bae93a24b138c1cd8e8,
title = "Engineering organs",
abstract = "Applications of regenerative medicine technology may offer novel therapies for patients with injuries, end-stage organ failure, or other clinical problems. Currently, patients suffering from diseased and injured organs can be treated with transplanted organs. However, there is a severe shortage of donor organs that is worsening yearly as the population ages and new cases of organ failure increase. Scientists in the field of regenerative medicine and tissue engineering are now applying the principles of cell transplantation, material science, and bioengineering to construct biological substitutes that will restore and maintain normal function in diseased and injured tissues. The stem cell field is also advancing rapidly, opening new avenues for this type of therapy. For example, therapeutic cloning and cellular reprogramming may one day provide a potentially limitless source of cells for tissue engineering applications. Although stem cells are still in the research phase, some therapies arising from tissue engineering endeavors have already entered the clinical setting successfully, indicating the promise regenerative medicine holds for the future.",
author = "Anthony Atala",
year = "2009",
month = "10",
day = "1",
doi = "10.1016/j.copbio.2009.10.003",
language = "English",
volume = "20",
pages = "575--592",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Engineering organs

AU - Atala, Anthony

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Applications of regenerative medicine technology may offer novel therapies for patients with injuries, end-stage organ failure, or other clinical problems. Currently, patients suffering from diseased and injured organs can be treated with transplanted organs. However, there is a severe shortage of donor organs that is worsening yearly as the population ages and new cases of organ failure increase. Scientists in the field of regenerative medicine and tissue engineering are now applying the principles of cell transplantation, material science, and bioengineering to construct biological substitutes that will restore and maintain normal function in diseased and injured tissues. The stem cell field is also advancing rapidly, opening new avenues for this type of therapy. For example, therapeutic cloning and cellular reprogramming may one day provide a potentially limitless source of cells for tissue engineering applications. Although stem cells are still in the research phase, some therapies arising from tissue engineering endeavors have already entered the clinical setting successfully, indicating the promise regenerative medicine holds for the future.

AB - Applications of regenerative medicine technology may offer novel therapies for patients with injuries, end-stage organ failure, or other clinical problems. Currently, patients suffering from diseased and injured organs can be treated with transplanted organs. However, there is a severe shortage of donor organs that is worsening yearly as the population ages and new cases of organ failure increase. Scientists in the field of regenerative medicine and tissue engineering are now applying the principles of cell transplantation, material science, and bioengineering to construct biological substitutes that will restore and maintain normal function in diseased and injured tissues. The stem cell field is also advancing rapidly, opening new avenues for this type of therapy. For example, therapeutic cloning and cellular reprogramming may one day provide a potentially limitless source of cells for tissue engineering applications. Although stem cells are still in the research phase, some therapies arising from tissue engineering endeavors have already entered the clinical setting successfully, indicating the promise regenerative medicine holds for the future.

UR - http://www.scopus.com/inward/record.url?scp=70449643153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449643153&partnerID=8YFLogxK

U2 - 10.1016/j.copbio.2009.10.003

DO - 10.1016/j.copbio.2009.10.003

M3 - Article

C2 - 19896823

AN - SCOPUS:70449643153

VL - 20

SP - 575

EP - 592

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

IS - 5

ER -